CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
How is CancerIQ working to make genetic services more practical in predicting or preventing cancer?
So, CancerIQ is making it more practical to start predicting and pre-empting cancer by really trying to reduce some of the barriers that are really holding the industry back today. The first of those challenges is really knowledge. You know, to connect the dots on people’s family history, and their genetic testing information. Really stuff that the provider can’t do with the naked eye. So, it’s really through our software that we can automate the decisions that need to be made on the basis of that information, and make it relatively easy for the physician, who, quite frankly, didn’t study genetics when they were in medical school.
The second way that CancerIQ makes it practical for people to do this in routine care is being really mindful of the clinical workflow. Unfortunately, people are today using systems that are primarily oriented for billing and logging of information. And CancerIQ works really well with those systems in being a layer of intelligence on top of that. So, how we actually integrate into your everyday clinical workflow is really connecting to the systems that already exist but putting that layer of intelligence on top of it.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More